The importance of Epstein-Barr virus infection in the systemic treatment of patients with gastric cancer
Copyright © 2020 Elsevier Inc. All rights reserved..
The Epstein-Barr virus (EBV) may directly cause the development of EBV-associated gastric cancer (EBVaGC). The prevalence of EBVaGC ranges from 4% to 18%, with a 2-fold higher frequency in males, and in tumors arising in the gastric cardia or corpus and 4 times higher frequency in gastric stump carcinoma. The vast majority of EBVaGC are lymphoepithelioma-like carcinomas. Despite extensive nodal involvement and distant metastases at initial diagnosis, EBVaGC seems to be a distinct etiologic entity with a favorable prognosis. However, the lymphoepithelioma-like carcinomas subtype in EBVaGC cannot be recognized in the current molecular classifications. Neither is there an association between EBV positivity and survival of patients after curative gastrectomy if they received standard adjuvant chemotherapy, nor EBV positivity and prediction of response to neoadjuvant platinum/5-FU-based chemotherapy. Alterations in chemokines and PD-L1 provide theoretical justification for clinical evaluation of immune checkpoint therapy in EBVaGC. Moreover, a higher degree of host immune response was demonstrated in EBVaGC. The current histologic and molecular GC classification does not influence clinical practice. Further research is expected to find convenient methods to assess gastric subtypes in day-to-day practice and to tailor therapy to improve overall survival.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Seminars in oncology - 47(2020), 2-3 vom: 15. Apr., Seite 127-137 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pikuła, Agnieszka [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EBV infection |
|---|
| Anmerkungen: |
Date Completed 22.01.2021 Date Revised 22.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1053/j.seminoncol.2020.04.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30985444X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30985444X | ||
| 003 | DE-627 | ||
| 005 | 20231225134825.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1053/j.seminoncol.2020.04.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM30985444X | ||
| 035 | |a (NLM)32402473 | ||
| 035 | |a (PII)S0093-7754(20)30033-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pikuła, Agnieszka |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The importance of Epstein-Barr virus infection in the systemic treatment of patients with gastric cancer |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2021 | ||
| 500 | |a Date Revised 22.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a The Epstein-Barr virus (EBV) may directly cause the development of EBV-associated gastric cancer (EBVaGC). The prevalence of EBVaGC ranges from 4% to 18%, with a 2-fold higher frequency in males, and in tumors arising in the gastric cardia or corpus and 4 times higher frequency in gastric stump carcinoma. The vast majority of EBVaGC are lymphoepithelioma-like carcinomas. Despite extensive nodal involvement and distant metastases at initial diagnosis, EBVaGC seems to be a distinct etiologic entity with a favorable prognosis. However, the lymphoepithelioma-like carcinomas subtype in EBVaGC cannot be recognized in the current molecular classifications. Neither is there an association between EBV positivity and survival of patients after curative gastrectomy if they received standard adjuvant chemotherapy, nor EBV positivity and prediction of response to neoadjuvant platinum/5-FU-based chemotherapy. Alterations in chemokines and PD-L1 provide theoretical justification for clinical evaluation of immune checkpoint therapy in EBVaGC. Moreover, a higher degree of host immune response was demonstrated in EBVaGC. The current histologic and molecular GC classification does not influence clinical practice. Further research is expected to find convenient methods to assess gastric subtypes in day-to-day practice and to tailor therapy to improve overall survival | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a EBV infection | |
| 650 | 4 | |a Epstein-Barr virus | |
| 650 | 4 | |a Gastric cancer | |
| 650 | 4 | |a MSI | |
| 650 | 4 | |a Molecular classification | |
| 650 | 4 | |a Multimodality treatment | |
| 700 | 1 | |a Kwietniewska, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Rawicz-Pruszyński, Karol |e verfasserin |4 aut | |
| 700 | 1 | |a Ciseł, Bogumiła |e verfasserin |4 aut | |
| 700 | 1 | |a Skórzewska, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Gęca, Katarzyna |e verfasserin |4 aut | |
| 700 | 1 | |a Franciszkiewicz-Pietrzak, Kinga |e verfasserin |4 aut | |
| 700 | 1 | |a Kurylcio, Andrzej |e verfasserin |4 aut | |
| 700 | 1 | |a Mielko, Jerzy |e verfasserin |4 aut | |
| 700 | 1 | |a Polkowski, Wojciech P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in oncology |d 1974 |g 47(2020), 2-3 vom: 15. Apr., Seite 127-137 |w (DE-627)NLM000122998 |x 0093-7754 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2020 |g number:2-3 |g day:15 |g month:04 |g pages:127-137 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1053/j.seminoncol.2020.04.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2020 |e 2-3 |b 15 |c 04 |h 127-137 | ||